Cash and cash equivalents of $115.8 million at March 31, 2025 compared to $132.2 million at year ended September 30, 2024. As of quarter end, the Company anticipates at current cash utilization rates and ranges, a runway of approximately 4 years.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Largest borrow rate increases among liquid names
- Anavex Life Sciences (AVXL) Q2 Earnings Cheat Sheet
- Anavex Life Sciences: Promising Developments and Strategic Growth Opportunities Justify Buy Rating
- Anavex announces full enrollment fo Phase 2 study of ANAVEX 3-71
- Anavex appoints Audrey Gabelle to Scientific Advisory Board